Sands Capital Life Sciences Pulse Fund, LLC's Form 4 filing
Acumen Pharmaceuticals, Inc. (ABOS) · filed Jul 8, 2021
- Accession no.
- 0000899243-21-027891
- Filed
- Jul 8, 2021, 5:21 PM ET
- Trade date
- Jul 6, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $6.70M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sands Capital Life Sciences Pulse Fund, LLCCIK 0001870490 | 10% Owner |
| Sands Capital Ventures Discovery Fund III, L.P.CIK 0001870491 | 10% Owner |
| Sands Capital Global Venture Fund II, L.P.CIK 0001870493 | 10% Owner |
| Sands Frank M.CIK 0001870494 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 6, 2021 | Common Stock | CConversionAcquired | +1,124,729 | –F1 | – | 1,124,729 | Direct | |
| Jul 6, 2021 | Common Stock | CConversionAcquired | +1,842,346 | –F1 | – | 2,967,075 | Direct | |
| Jul 6, 2021 | Common Stock | PPurchaseAcquired | +450,000 | $14.88 | +$6,696,000 | 3,417,075 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock automatically converted into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.